Solanbridge Group acquires majority interest in Buzznbrewz.com

NewsGuard 100/100 Score

Solanbridge Group Inc (OTC: SLNX) is pleased to announce that SLNX has acquired the majority interest in Buzznbrewz.com and the Letter of Intent issued on July 11, 2014 has been replaced with a fully executed Purchase Agreement.

Charles R. Shirley, Managing Director of Solanbridge, stated "We are proud to have Mr. David Pecoraro and Buzznbrewz.com join SLNX's team. David has decades of experience in the private sector and developed a tremendous network of contacts who have been helpful to SLNX's effort in the past and will be again in the future."

David Pecoraro is a 52 year old entrepreneur. He writes a social media newsletter that follows trends of long term investment waves. At the same time, David developed a transportation business, specializing in high value items, successfully involved with high profile projects. In the previous 20 years, David was involved in the wholesale, retail and distribution of grocery/retail and restaurants. David held positions in sales and management for Durkee/Frenchs and other companies, in production, distribution specialist in opening new stores and accounts.

Solanbridge expects Buzznbrewz.com to generate revenues from its line of beer brewing, coffee, vapor, cigars, vitamin, and cannabis paraphernalia products within the next two weeks.

On July 11, 2014, SLNX signed a Letter of Intent (LOI) to acquire majority interest in Buzznbrewz.com, specifically an eighty percent (80%) interest. On July 24, 2014, SLNX and Buzznbrewz.com fully executed a definitive Purchase Agreement to acquire Buzznbrewz.com, closing the LOI and making Buzznbrewz.com SLNX's newest subsidiary.

Source:

Solanbridge Group Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Prenatal cannabis use disorder linked to increased risk of neurodevelopmental disorders in offspring